Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2019 08:20 ET | Source: VAYA Pharma Inc.

fMRI Data from Clinical Trial Demonstrate a Proposed Mechanism of Action for the Efficacy of Vayarin® Plus in Adults with ADHD

Study Abstract Presented at the 2019 APSARD Annual Meeting in Washington, DC COLUMBIA, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and...
October 26, 2018 10:14 ET | Source: VAYA Pharma Inc.

New Clinical Trial Demonstrates Efficacy and Safety of Vayarin® Plus for Adults with ADHD

COLUMBIA, Md., Oct. 26, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and leader in developing specialty nutrition and medical food products, announced today that...
October 09, 2018 08:30 ET | Source: VAYA Pharma Inc.

New Data from Adult ADHD Clinical Trial to be Presented at the 65th Annual AACAP Meeting

COLUMBIA, Md., Oct. 09, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc., and leader in developing specialty nutrition and medical food products, announced today the...
June 04, 2018 09:23 ET | Source: VAYA Pharma Inc.

VAYA™ Pharma Launches Vayarin® Plus Medical Food for the Management of ADHD in Adults and Adolescents

COLUMBIA, MD., June 04, 2018 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Industries Ltd. (LSE:FRUT) (TASE:FRUT) and a leader in specialty nutrition and medical food...
May 02, 2017 08:30 ET | Source: VAYA Pharma Inc.

VAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods

BALTIMORE, May 02, 2017 (GLOBE NEWSWIRE) -- VAYA Pharma, a division of Enzymotec Ltd (NASDAQ:ENZY) and innovator of lipid-based medical foods, today announced the availability of new three-month...
January 24, 2017 13:03 ET | Source: VAYA Pharma Inc.

CORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study

BALTIMORE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline January 10, 2017 by VAYA Pharma, please note that in the first paragraph under Results at a Glance, "38...
January 10, 2017 11:33 ET | Source: VAYA Pharma Inc.

Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study

BALTIMORE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according to Research in...
May 04, 2016 09:00 ET | Source: VAYA Pharma Inc.

New Survey Shows Nearly 3 Out of 4 Children Treated for ADHD Have Taken a “Drug Holiday”

National VAYA™ Pharma Survey Reveals Drug Holidays are Mostly Prompted by Physicians and the Desire to Reduce Medication Side Effects BALTIMORE, May 04, 2016 (GLOBE NEWSWIRE) -- Approximately...
April 26, 2016 11:07 ET | Source: VAYA Pharma Inc.

New Retrospective Study Shows PS-Omega-3 Medical Food Effective in Managing ADHD

Nearly a Third of Children Who Experienced a Benefit While Taking PS-Omega-3 Were Also Able to Reduce Their ADHD Medication Dose BALTIMORE, April 26, 2016 (GLOBE NEWSWIRE) -- According to a new...